This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the INLYTA® (axitinib​​​​​​​) Summary of Product Characteristics for Great Britain. 
INLYTA® (axitinib) Prescribing Information ​​​​​​​click here.  Adverse event reporting information can be found at the bottom of the page.

INLYTA® resources for your patients and their carers

Click ‘Download to browse content’ to view each piece for electronic viewing only.
If this material is shared with patients it must be downloaded and NOT shown directly to patients from this website, which is intended for UK healthcare professionals only.

Carers’ information brochure

This booklet is for anyone who is looking after someone who has been prescribed INLYTA® (axitinib) to treat advanced renal cell carcinoma. 

Download to browse content

Treatment information brochure

Brochure offering guidance and support for patients who have been prescribed INLYTA® (axitinib) to help treat advanced renal cell carcinoma.

Download to browse content

ByYourSideTM patient brochure

A brochure containing information on the ByYourSideTM programme for people in the UK living with cancer, and their loved ones.

Download to browse content

 renal cell carcinoma

  1. INLYTA® Summary of Product Characteristics for Great Britain click here. INLYTA® Summary of Product Characteristics for Northern Ireland click here.
PP-INL-GBR-0843 July 2022

Support & Resources

  • Patient support
  • HCP resources
  • Videos
  • Materials


  • INLYTA® is indicated for the treatment of adult patients with advanced renal cell carcinoma (aRCC) after failure of prior treatment with sunitinib or a cytokine.1

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?